3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
113
Neoplasm Metastasis
5
Carcinoma, Intraductal, Noninfiltrating
5
Polycystic Ovary Syndrome
4
Ovarian Neoplasms
4
Osteoporosis
4
Neoplasms
4
Infertility
4
Breast Neoplasms, Male
4
Arthralgia
4
Fallopian Tube Neoplasms
3
Triple Negative Breast Neoplasms
2
Pain
2
Leiomyosarcoma
2
Leiomyoma
2
Endometrial Neoplasms
2
Cystadenocarcinoma, Serous
2
Breast Carcinoma In Situ
2
Bone Diseases, Metabolic
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cysts
1
Osteitis Deformans
1
Obesity
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphoma, Non-Hodgkin
1
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Letrozole
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts